[go: up one dir, main page]

CN1165509C - Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs - Google Patents

Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs Download PDF

Info

Publication number
CN1165509C
CN1165509C CNB021149739A CN02114973A CN1165509C CN 1165509 C CN1165509 C CN 1165509C CN B021149739 A CNB021149739 A CN B021149739A CN 02114973 A CN02114973 A CN 02114973A CN 1165509 C CN1165509 C CN 1165509C
Authority
CN
China
Prior art keywords
hoc
cophnh
phnh
phs
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021149739A
Other languages
Chinese (zh)
Other versions
CN1374288A (en
Inventor
古练权
刘宗潮
黄志纾
段志芳
马林
谢冰芬
朱孝峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CNB021149739A priority Critical patent/CN1165509C/en
Publication of CN1374288A publication Critical patent/CN1374288A/en
Application granted granted Critical
Publication of CN1165509C publication Critical patent/CN1165509C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及紫草萘醌类衍生物及其在制备用于治疗癌症的药物中的应用。实验证明，紫草萘醌类衍生物对于肿瘤细胞株CNE2、Glc-82、S180A、EAC、HepA等具有显著的抑制作用，人癌细胞裸鼠移植瘤模型研究也证明了紫草萘醌类衍生物的抗癌作用。紫草萘醌类衍生物的化学结构式如式I所示，式中R1、R2、R2如说明书所定义。

The invention relates to shikonaquinone derivatives and their application in the preparation of medicines for treating cancer. Experiments have proved that shikonaquinone derivatives have significant inhibitory effects on tumor cell lines CNE 2 , Glc-82, S 180A , EAC, HepA, etc. The study on human cancer cell xenograft model also proved that shkonaquinone Anticancer effects of derivatives. The chemical structural formula of shikonaquinone derivatives is shown in formula I, wherein R 1 , R 2 , and R 2 are as defined in the description.

Description

Gronwell naphthaquinone derivative and the application in the preparation cancer therapy drug thereof
Technical field
The present invention relates to a class Gronwell naphthaquinone derivative and be used for the treatment of purposes in the medicine of cancer in preparation.
Technical background
Cancer is current to one of maximum disease of human health and quality of life harm.The exploitation of cancer therapy drug is the hot subject of scientists study always.Because the complicacy and the singularity of cancer mechanism are sought highly selective, are efficiently reached low toxicity, the little cancer therapy drug of side effect, do not obtain ideal results.
The contained naphthoquinone compound of plurality of Chinese has been found has certain anti-tumor activity, but as from the isolating beta-hydroxyisovalerylshiderivative inducing leukemia of gromwell root root HL-60 apoptosis; β, beta-dimethyl-acry-lalkannin to Human Prostate Cancer Cells (DU145, LNCaD, PC-3) inhibited; The lithospermum euchromum Royle element has restraining effect to colorectal cancer cells, and makes apoptosis etc.Just, still fail at present in clinical use [institute of Materia Medica,Chinese Academy of Medical Sciences, herbal medicine modern study (second volume), p274,, Beijing Medical University-combined publication society of China Concord Medical Science University in 1996] because their anti-tumor activity is not high enough.
Summary of the invention
The purpose of this invention is to provide the Gronwell naphthaquinone derivative shown in the formula I and be used for the treatment of application in the medicine of cancer in preparation.The present invention experiment showed, that Gronwell naphthaquinone derivative has significant inhibitory effect for various tumor cell strains, and the model research of human cancer cell transplanted tumor in nude mice has also proved the antitumous effect of Gronwell naphthaquinone derivative.
We find that they can react with different nucleophilic reagents, generate the derivative of different replacement degree, different the position of substitution when research Gronwell naphthaquinone compound chemistry reaction property.These derivatives are carried out the cancer cell in vitro inhibition test show, they to the cytotoxicity of multiple cancer cells than natural Gronwell naphthaquinone compound much better than (50～250 times).Carrying out in vivo test with human cancer cell transplanted tumor in nude mice model has proved the derivative of natural Gronwell naphthaquinone compound through obtaining after the chemically modified, has good antitumour activity.
Gronwell naphthaquinone derivative of the present invention is as with shown in the following formula I:
Figure C0211497300031
Formula I
R among the formula I 1, R 2, R 3The group of representative can be one of and the following:
(1), R 1Be OH, (CH 3) 2C=CHCOO, CH 2COO or CH 3COOC (CH 3) 2CH 2COO; R 2Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S; R 3Be H;
(2), R 1Be OH, (CH 3) 2C=CHCOO, CH 3COO or CH 3COOC (CH 3) 2CH 2COO; R 2Be H; R 3Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S;
(3), R 1Be OH, (CH 3) 2C=CHCOO, CH 3COO or CH 3COOC (CH 3) 2CH 2COO; R 2Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S; R 3Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S, HOC 2H 4S or C 2H 5S;
(4), R 1Be PhNH, p-CH 3COPhNH, PhS, HOC 2H 4S or C 2H 5S; R 2Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S; R 3Be H;
(5), R 1Be PhNH, p-CH 3COPhNH, PhS, HOC 2H 4S or C 2H 5S; R 2Be H; R 3Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S;
(6), R 1Be PhNH, p-CH 3COPhNH, PhS, HOC 2H 4S or C 2H 5S; R 2Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S; R 3Be (CH 3) 2N, PhNH, p-CH 3COPhNH, Ph-N-CH 3, PhS, HOC 2H 4S or C 2H 5S;
(7), R 1Be OH, CH 3) 2C=CHCOO, CH 3COO or CH 3COOC (CH 3) 2CH 2COO; R 2=R 3=H.
Gronwell naphthaquinone derivative shown in the formula I of the present invention can generate the Gronwell naphthaquinone derivative of different replacement degree, different the position of substitution by natural Gronwell naphthaquinone compound and different nucleophilic reagent reactions.
The said natural Gronwell naphthaquinone compound of the present invention, for example Shikonin (shikonin), acetylshikonin (acetyshikonin), β, (β, β-dimethyacrylalkannin) wait and can extract from Asian puccoon makes through separation and purifying beta-dimethyl-acry-lalkannin.
The present invention shows that by the cancer cell in vitro inhibition test Gronwell naphthaquinone derivative has very strong cytotoxicity to multiple cancer cells.
The present invention has proved that by the in vivo test of human cancer cell transplanted tumor in nude mice model Gronwell naphthaquinone derivative has good antitumour activity.
The present invention tests by animal pharmacology, determines that the using dosage scope of Gronwell naphthaquinone derivative or its pharmacy combination is 10～100mg/kg/day.
The present invention tests by animal toxicology, determines that Gronwell naphthaquinone derivative is the medicine that class toxic side effect in the dose therapeutically effective scope is little, can take for a long time.
According to the present invention, compound shown in the above-mentioned formula I or the combination of its pharmacy can be made the form of injection, tablet, pill, capsule, suspension agent, emulsion and be used; That its route of administration can be is oral, through skin, vein or muscle.
Embodiment
The present invention will be further described by the following examples.
Embodiment one: the extraction of Shikonin compounds, separation and purifying
Shikonin compounds [R 1=OH, (CH 3) 2C=CHCOO, CH 3COO or CH 3COOC (CH 3) 2CH 2COO, R 2=R 3=H] be configured as the R-type, content is higher in Yunnan Asian puccoon (Onosma confertum W.W.Smith).
Take by weighing close colored Yunnan, the Sichuan Asian puccoon of 5kg, ground 20 mesh sieves, carry out normal temperature percolation with 95% ethanol and extract, till closely colourless.United extraction liquid, concentrating under reduced pressure adds the 2%NaOH that is equivalent to 1/3～1/2 concentrated solution volume in concentrated solution, and solution becomes blueness by red-purple.Add dense HCl acidifying after removing by filter insolubles, this moment, solution became red-purple by blueness, had a large amount of throw outs to generate standing over night simultaneously.Leach throw out, be washed till nearly neutrality with distilled water.With drying precipitate, get the about 60g of pulverulent solids crude product.Crude product is dissolved with methylene dichloride, add an amount of stirring of silica gel and spare, volatilize the back upper prop naturally.The filler of chromatographic column is 120～160 order silica gel, eluent sherwood oil (60～90 ℃)-acetone and sherwood oil-acetone-trichloromethane, wash-out and collection successively.Concentrate after recrystallization obtains following four Shikonin compounds respectively: Shikonin (Shikonin, 1) 0.60g, acetylshikonin (acetylshikonin, 2) 0.85g, β, beta-dimethyl-acryloyl Shikonin (β, β-dimethylacrylshikonin, 3) 2.30g, β-acetoxyl group isovaleryl Shikonin (β-acetoxyisovalerylshikonin, 4) 0.93g.Product structure MNR, MSUV and ultimate analysis data is determined.
Compound 1 compound 2
Compound 3 compounds 4
Embodiment two: the extraction of acarnine naphthoquinone compound, separation and purifying
Alkannin compound [R 1=OH, (CH 3) 2C=CHCOO, CH 3COO or CH 3COOC (CH 3) 2CH 2COO, R 2=R 3=H] the S-type that is configured as of naphthoquinone derivatives, content is higher in Xinjiang Radix Arnebiae [Arnebia euchroma (Royle) Johust].
After Radix Arnebiae dried root 5kg in Xinjiang pulverizes,, extract twice in soaking at room temperature with sherwood oil (30～60 ℃) 12 liters.After leaching liquid filters,, get the about 80g of dark red paste through normal pressure and decompression desolventizing.Should extract enriched material silica gel column chromatography rough segmentation,, obtain four red component of opposed polarity solvent elution with sherwood oil (69-90 ℃)-ethyl acetate gradient elution.Further carry out separation and purification, use the petroleum ether-ethyl acetate gradient elution with quick silica gel column chromatography.Isolate four redness or red-purple material at last: A Kaning (alkannin, 5) 1.20g, acetyl A Kaning (acetylalkannin, 6) 1.65g, β, beta-dimethyl-acry-lalkannin (β, β-dimethylacrylalkannin, 7) 2.85g, β-acetoxyl group isovaleryl A Kaning (β-acetoxyisovalerylalkannin, 8) 1.42g.Product structure UV, IR, NMR is analyzed definite.
Figure C0211497300061
Compound 5 compounds 6
Figure C0211497300062
Compound 7 compounds 8
Embodiment three: R 2Or R 3Synthetic for the Asian puccoon naphthoquinone derivatives of substituted benzene amino
With 0.2mmol β, the methanol solution (8mL) of beta-dimethyl-acry-lalkannin and 1mmol aniline is stirring reaction 6 days at room temperature, follows the tracks of reaction with TLC.After reaction is finished, the decompression desolventizing, crude product separates (is eluent with the petroleum ether-ethyl acetate solvent) with rapid column chromatography, obtains the product (9,10) that C-7 or C-8 position hydrogen are replaced by aryl amine, overall yield about 80%.
Use identical method, use β, beta-dimethyl-acry-lalkannin is a raw material, can synthetic compound 11 and 12.
Figure C0211497300064
Compound 11 compounds 12
(OR＝(CH 3) 2C＝CHCOO)
Embodiment four: R 1Be substituted benzene amino, R 2Or R 3Synthetic for the Asian puccoon naphthoquinone derivatives of substituted benzene amino
At ice bath with under stirring, once with NaBH 4Solid (0.45mmol) is added to 0.2mmol β, in the methanol solution of beta-dimethyl-acry-lalkannin and 1mmol aniline (8mL), red solution becomes faint yellow immediately, at room temperature continues to stir 12 hours, yellow solution gradually becomes red-purple again, and the TLC detection reaction is complete.The decompression desolventizing, crude product separates (is eluent with the petroleum ether-ethyl acetate solvent) with rapid column chromatography, obtains C-11 position ester group and is replaced by aryl amine, the red-purple product (13,14) that while C-7 or C-8 position hydrogen are replaced by aryl amine, overall yield about 75%.
Figure C0211497300071
Embodiment five: R 1Be thiophenyl, R 2Or R 3Synthetic for the Asian puccoon naphthoquinone derivatives of thiophenyl
With 0.2mmol β, the methanol solution (8mL) of beta-dimethyl-acry-lalkannin and 0.45mmol thiophenol is stirring reaction 8 hours at room temperature, follows the tracks of reaction with TLC.The decompression desolventizing, crude product separates (is eluent with the petroleum ether-ethyl acetate solvent) with rapid column chromatography, obtains C-11 position ester group and is substituted, the red-purple product (15,16) that while C-7 or C-8 position hydrogen are replaced by aromatic thiohydroxy, overall yield about 85%.
Figure C0211497300072
Use identical method, use β, beta-dimethyl-acry-lalkannin is a raw material, can synthetic compound 17 and 18.
Figure C0211497300081
Compound 17 compounds 18
Embodiment six: R 1Be thiophenyl, R 2Or R 3Synthetic for the Asian puccoon naphthoquinone derivatives of anilino
With compound 9 or 10 and the long-time stirring and refluxing of methanol solution of thiophenol, follow the tracks of reaction with TLC.The decompression desolventizing, crude product separates (is eluent with the petroleum ether-ethyl acetate solvent) with rapid column chromatography, obtains C-11 position ester group and is replaced by thiophenyl, the red-purple product (19,20) that while C-7 or C-8 position hydrogen are replaced by aryl amine, overall yield about 75%.
Figure C0211497300082
Embodiment seven: R 1, R 2And R 3Be Asian puccoon naphthoquinone derivatives synthetic of sulfydryl
With 0.2mmol β, the methanol solution of the 2 mercapto ethanol of beta-dimethyl-acry-lalkannin and 1mmol (10mL) is stirring reaction 3d at room temperature, the decompression desolventizing, crude product separates (is eluent with the petroleum ether-ethyl acetate solvent) with rapid column chromatography, can obtain R 1, R 2And R 3Be the red-purple compound (21) of sulfydryl, productive rate about 88%.
Embodiment eight: β, beta-dimethyl-acry-lalkannin (7) * and derivative thereof be to S180, EAC, the cytotoxicity method of HepA: mtt assay.S180, FAC and the HepA cell of taking the logarithm and growing are diluted to 2 * 10 respectively 4Individual/mL, be sub-packed in 96 orifice plates (0.2mL/ hole).If there is not the medicine control group, the tested compounds of DMSO control group and 5 different concns, every hole 10 μ L.Each group is established 4 parallel holes, puts 37 ℃, 5% CO 2Cultivate 72h in the incubator.4h added MTT liquid (5mg/mL) 10 μ L/ holes before experiment stopped, and cultivated 4h again.Discard nutrient solution, add DMSO 100 μ L/ holes, the mixing vibration is dissolved the brilliant first Za of knot fully, under the 570nm wavelength, measures the OD value with BioRad produced in USA 550 type microplate reader, goes out inhibitory rate of cell growth (half-inhibition concentration, IC by following formula 50).
Growth inhibition ratio=(the average OD value of the average OD value/control group of 1-medication group) * 100%
IC 50Be worth more for a short time, the cytotoxicity of this compound is big more.
* in the natural Asian puccoon naphthoquinone compound, β, beta-dimethyl-acry-lalkannin (7) activity is the highest, and we select this compound as standard, the activity of more various synthetic Asian puccoon naphthoquinone derivatives.
Table 1. β, beta-dimethyl-acry-lalkannin (7) and derivative thereof be to S180, EAC, the cytotoxicity (IC of HepA 50)
Cell strain Compound number/IC 50(μg/mL)
7 9 10 13 14 16
S180 300 80 76 50 40 1.92
EAC 250 80 70 30 35 1.17
HepA 280 85 81 50 50 1.54
The result shows that compound 7 (β, beta-dimethyl-acry-lalkannin) is less to the cytotoxicity of S180, EAC and HepA; The cytotoxicity of compound 9,10,13,14 strengthens 3-8 doubly than 7, demonstrates the moderate cytotoxicity; The cytotoxicity of compound 16 is very strong, strengthens 156-213 doubly than the cytotoxicity of compound 7, demonstrates strong cytotoxicity.
Embodiment nine: β, beta-dimethyl-acry-lalkannin (7) and derivative thereof are to the restraining effect of 5 kinds of human cancer cells
Method: mtt assay.Experimental technique is with embodiment eight.
Table 2. β, beta-dimethyl-acryloyl Ah Ka (7) and other 5 derivatives are to the restraining effect of 5 kinds of human cancer cells
Group Drug level Inhibiting rate (%)
(μg/ml) Nasopharyngeal carcinoma CNE2 Mammary cancer MCF-7 Liver cancer Bel-7402 Lung cancer GLC-82 Large bowel cancer HT-29
Compound 7 100 27.8 31.2 29.3 38.5 21.8
200 48.3 41.3 39.8 43.8 39.6
400 755 69.7 70.2 84.5 62.3
Compound 9 40 30.4 41.1 38.5 30.3 29.4
70 57.3 61.8 47.6 50.8 48.5
100 93.1 84.3 89.8 87.5 79.8
Compound 10 50 40.3 41.5 32.2 28.7 39.6
80 57.6 63.3 56.4 64.3 60.4
110 88.3 90.2 87.3 95.5 95.0
Compound 13 20 27.3 40.2 42.8 39.5 35.6
50 67.3 54.3 64.3 48.3 56.9
80 98.8 84.8 93.2 87.6 89.0
Compound 14 20 27.3 38.4 40.3 47.5 32.3
50 59.6 49.2 63.8 53.8 44.6
80 88.7 73.5 87.5 89.4 87.8
Compound 16 0.8 29.9 32.8 41.0 38.3 39.3
1.4 67.4 53.4 63.8 49.2 47.7
2.0 97.3 84.3 92.7 87.2 90.5
Compound 18 0.8 35.3 40.5 39.8 41.8 42.1
1.4 64.7 70.3 69.3 72.9 68.7
2.0 91.3 94.4 89.4 98.6 97.6
The result shows, compound 16 and 18 pairs of nasopharyngeal carcinoma, mammary cancer, liver cancer, lung cancer and large bowel cancers have a significant inhibitory effect.
Embodiment ten: the restraining effect of the compound 16 and the 18 pairs of nasopharyngeal carcinoma and liver cancer transplanted tumor in nude mice
The KB cell CNE2 or the liver cancer cell Bel-7402 that take the logarithm and grow are with being made into 1 * 10 after the trysinization 7Individual/the mL single cell suspension, under aseptic condition, be inoculated in the BALB/C nude mouse and keep right that O.2mL/ armpit is subcutaneous only (is equivalent to 2 * 10 6Individual cell).Inoculate back 7 days, when treating that tumour is grown to diameter 3-5mm, size by volume is divided into the basic, normal, high dosage group of control group, 5-Fu group (positive drug control group), compound 16 and 18, every group of 8 mouse at random.Began administration the same day after the grouping, abdominal injection, and be administered once every day, and 6 times weekly, 3 weeks of logotype.Drug withdrawal is weighed next day, puts to death nude mice, strips out the record of weighing behind the knurl piece, calculates average tumor weight, calculates tumour inhibiting rate by following formula, and does the t test.
Tumour inhibiting rate=(the average tumor weight of the average tumor weight/control group of 1-experimental group) * 100%
The restraining effect of 16,18 pairs of human nasopharyngeal carcinomas of table 3. compound and liver cancer cell Bel-7402 transplanted tumor in nude mice
Grouping Dosage Knurl strain and inhibiting rate (%)
(mg/kg) Nasopharyngeal carcinoma cell CNE Liver cancer cell Bel-7402
Control group N.S 0 0
5-Fu (positive control) group 25 62.5 57.4
Compound 16 20 37.2 41.5
50 59.3 56.3
80 77.9 71.6
Compound 18 20 60.0 54.3
50 72.2 69.0
80 87.5 82.1
The result shows that compound 16 and 18 has the good restraining effect to nasopharyngeal carcinoma and liver cancer cell transplanted tumor in nude mice model under the animal tolerance dose, and inhibiting rate and dosage are proportionate.
Practicality pharmaceutically
The above embodiment of the present invention shows:
(1) by Gronwell naphthaquinone derivative to cancer cells inhibition test and cancer cells transplanted tumor in nude mice model trial, proved that natural Gronwell naphthaquinone compound has good antitumour activity through the derivative that obtains after the chemically modified.
(2) use Gronwell naphthaquinone derivative shown in the formula 1 of the present invention, the using dosage scope is 10～100mg/kg/day.
(4) use Gronwell naphthaquinone derivative shown in the formula 1 of the present invention, under normal dose, it is safe as medicinal application.
(5) use the combination of compound shown in the formula 1 of the present invention or its pharmacy, have that anticancer effect is good, side effect is little and the characteristics of applied range.

Claims (5)

1.式I所示的紫草萘醌类衍生物：1. Shikonadhiquinone derivatives shown in formula I:
Figure C021149730002C1
Figure C021149730002C1
 式IFormula I 式I中的R1，R2，R3所代表的基团为以下各项之一：The groups represented by R 1 , R 2 , and R 3 in formula I are one of the following: (1)、R1为OH、(CH3)2C＝CHCOO、CH3COO或CH3COOC(CH3)2CH2COO；R2为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S；R3为H；(1), R 1 is OH, (CH 3 ) 2 C=CHCOO, CH 3 COO or CH 3 COOC(CH 3 ) 2 CH 2 COO; R 2 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH, Ph-N-CH 3 , PhS, HOC 2 H 4 S or C 2 H 5 S; R 3 is H; (2)、R1为OH、(CH3)2C＝CHCOO、CH3COO或CH3COOC(CH3)2CH2COO；R2为H；R3为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S；(2), R 1 is OH, (CH 3 ) 2 C=CHCOO, CH 3 COO or CH 3 COOC(CH 3 ) 2 CH 2 COO; R 2 is H; R 3 is (CH 3 ) 2 N, PhNH , p-CH 3 COPhNH, Ph-N-CH 3 , PhS, HOC 2 H 4 S or C 2 H 5 S; (3)、R1为OH、(CH3)2C＝CHCOO、CH3COO或CH3COOC(CH3)2CH2COO；R2为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S；R3为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S、HOC2H4S或C2H5S；(3), R 1 is OH, (CH 3 ) 2 C=CHCOO, CH 3 COO or CH 3 COOC(CH 3 ) 2 CH 2 COO; R 2 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH, Ph-N-CH 3 , PhS, HOC 2 H 4 S or C 2 H 5 S; R 3 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH, Ph-N-CH 3 , PhS, HOC 2 H 4 S, HOC 2 H 4 S or C 2 H 5 S; (4)、R1为PhNH、p-CH3COPhNH、PhS、HOC2H4S或C2H5S；R2为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S；R3为H；(4), R 1 is PhNH, p-CH 3 COPhNH, PhS, HOC 2 H 4 S or C 2 H 5 S; R 2 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH, Ph-N -CH 3 , PhS, HOC 2 H 4 S or C 2 H 5 S; R 3 is H; (5)、R1为PhNH、p-CH3COPhNH、PhS、HOC2H4S或C2H5S；R2为H；R3为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S；(5), R 1 is PhNH, p-CH 3 COPhNH, PhS, HOC 2 H 4 S or C 2 H 5 S; R 2 is H; R 3 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH , Ph-N- CH3 , PhS, HOC2H4S or C2H5S ; (6)、R1为PhNH、p-CH3COPhNH、PhS、HOC2H4S或C2H5S；R2为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S；R3为(CH3)2N、PhNH、p-CH3COPhNH、Ph-N-CH3、PhS、HOC2H4S或C2H5S。(6), R 1 is PhNH, p-CH 3 COPhNH, PhS, HOC 2 H 4 S or C 2 H 5 S; R 2 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH, Ph-N -CH 3 , PhS, HOC 2 H 4 S or C 2 H 5 S; R 3 is (CH 3 ) 2 N, PhNH, p-CH 3 COPhNH, Ph-N-CH 3 , PhS, HOC 2 H 4 S or C2H5S . 2.根据权利要求1所述的紫草萘醌类衍生物，其特征是该紫草萘醌类衍生物为天然紫草中分离纯化得到的化合物经过化学修饰后得到的产物。2. The shikonaquinone derivatives according to claim 1, characterized in that the shkonadhiquinone derivatives are chemically modified products obtained by separating and purifying natural comfrey. 3.权利要求1所述的式I的紫草萘醌类衍生物在制备用于治疗癌症的药物中的应用。3. The use of the shikonaquinone derivatives of formula I according to claim 1 in the preparation of medicines for treating cancer. 4.一种用于治疗癌症的药物，其中含有权利要求1的式I所示的紫草萘醌类衍生物，以及药学上可接受的辅助剂。4. A medicament for treating cancer, which contains the shkonadhiquinone derivatives shown in formula I of claim 1, and pharmaceutically acceptable auxiliary agents. 5.根据权利要求4所述的药物，其特征是所述药物是制成注射剂、片剂、丸剂、胶囊剂、悬浮剂或乳剂。5. The medicine according to claim 4, characterized in that the medicine is made into injection, tablet, pill, capsule, suspension or emulsion.
CNB021149739A 2002-03-19 2002-03-19 Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs Expired - Fee Related CN1165509C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021149739A CN1165509C (en) 2002-03-19 2002-03-19 Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021149739A CN1165509C (en) 2002-03-19 2002-03-19 Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs

Publications (2)

Publication Number Publication Date
CN1374288A CN1374288A (en) 2002-10-16
CN1165509C true CN1165509C (en) 2004-09-08

Family

ID=4743386

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021149739A Expired - Fee Related CN1165509C (en) 2002-03-19 2002-03-19 Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs

Country Status (1)

Country Link
CN (1) CN1165509C (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100455283C (en) * 2003-05-08 2009-01-28 北京金本草中药科技发展有限公司 Medicine containing alkannin compound as active ingredient
AU2007234746B2 (en) 2006-04-07 2009-10-01 Sunten Phytotech Co., Ltd. Naphthalenedione compounds
CN101265212B (en) * 2008-03-27 2010-07-28 上海交通大学 Shikonone oxime derivatives that can be used for antitumor
CN101683331B (en) * 2008-09-27 2013-01-30 厦门大学 Application of Shikonin Derivatives
KR20110051876A (en) * 2009-11-11 2011-05-18 남종현 Smoking Toxic Detoxification Composition
CN102198124B (en) * 2010-03-26 2014-10-29 山东靶点药物研究有限公司 Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof
CN102020598A (en) * 2010-11-11 2011-04-20 中山大学 Gronwell naphthaquinone derivative, preparation method of gronwell naphthaquinone derivative and application of gronwell naphthaquinone derivative serving as anticarcinoma drug
CN103054976B (en) * 2011-10-21 2014-09-24 上海中医药大学 A traditional Chinese medicine composition for treating thrombocytopenia and its preparation method and application
CN103086863B (en) * 2011-10-27 2014-10-29 复旦大学 Alkannin dimer compounds and uses of the same in drug preparation
CN103086864B (en) * 2011-10-31 2015-01-07 复旦大学 Shikonin tetramer compound and purpose thereof in pharmacy
CN103113335B (en) * 2011-11-17 2015-06-17 复旦大学 Benzoquinone compound and use thereof for preparing anti-tumour drug
CN103284983A (en) * 2013-05-10 2013-09-11 上海市肺科医院 Application of alkannin and/or derivative thereof in preparing medicine for prohibiting cancer cell metastasis
CN104130164B (en) * 2014-07-09 2016-05-04 上海交通大学 Racemic modification alkannin naphthazarine mother parent nucleus HM sodium sulfonate derivative
CN105601493A (en) * 2015-12-23 2016-05-25 江苏师范大学 Preparation method and application of alkannin analogue based on anthraquinone structure
CN108409570A (en) * 2018-03-06 2018-08-17 泰山医学院 Acetylshikonin rapidly and efficiently purification process in Asian puccoon

Also Published As

Publication number Publication date
CN1374288A (en) 2002-10-16

Similar Documents

Publication Publication Date Title
CN1165509C (en) Shikonadhiquinone Derivatives and Their Application in the Preparation of Anticancer Drugs
CN102702071A (en) New compound in henbane and preparation method and application thereof
CN1224383C (en) Blood sugar reducing compound
CN1308000C (en) Medicine containing pulsatilla root extuact as active component for curing solid tumor
CN101062029B (en) Application of wogonin in preparation of medicine for treating gastric cancer
CN100404524C (en) High-purity osthole, preparation method thereof, and pharmaceutical composition containing the compound as an active ingredient
CN101062041A (en) Novel medical function of cucurbitacin
CN101385749A (en) Application of Ailanthus ailanthus Extract in Preparation of Antineoplastic Drugs
CN106309484A (en) Application of sulfo-(seleno) phosphate cyclic dinucleotide cGAMP in cancer-treating drug combination
WO2008064558A1 (en) Bromo-dihydroartemisinin and its preparation
CN106928298A (en) The structure composition of ring dinucleotides cGAMP derivatives, preparation method and its application in antitumor
CN1582970A (en) Extraction of effective portion of gryllotalpidae for anti-cancers and its preparation
CN1193766C (en) Gardenia total glycoside composite for curing hepatitis and its preparation method
CN1775267A (en) A kind of open arrow extract and its preparation method and application
CN1850837A (en) 9-(1,3-benzo dioxolyl-5_)-4-(beta-D-glucopyranosyloxy)-6,7-dimethoxy naphthale [2,3-C] furna-1(3II] ketone, and its preparing method and medicinal composition containing same
CN101590035B (en) Application of dehydrogenated silybin in preparing anti-lung-cancer medicament
CN1224395C (en) Anti-tumor function of sophorine and its medicine preparation
CN1176677C (en) Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process
CN107362158B (en) Use of loganin in the preparation of antitumor drugs
CN104257641B (en) A kind of C36Polyacetylene compound and preparation thereof and application
CN104610207B (en) Gardenia sootepensis gardenin A, preparation method and medicinal application thereof
CN1613445A (en) Luteolin, its derivative and use for inhibiting enterocinesia
CN102477039A (en) Preparation method of Fissistigma Oldhamii lactam alkali compound and application of Fissistigma Oldhamii lactam alkali compound in preparation of antitumor drugs
CN1660067A (en) Application of liganans of biphenyl cyelo-octadiene in preparing antineoplastic medicine
CN101336918B (en) Application of anemone lactone compound in preparation of medicine for treating lung cancer or breast cancer

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040908

Termination date: 20160319